chevron_leftBack
As of 20 June 2026, BoYen Therapeutics, Inc. has a market cap of $14.87M USD, ranking #39046 globally and #2292 in Taiwan.
It ranks #3493 in the Healthcare sector, and #682 in the Biotechnology industry.
Key Stats
Market Cap
$14.87MUSD
470.21M TWD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
Founded
2010
Website
boyentherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.6% | -8.2% | -7.7% | -1.6% | -37% | -37% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
7891
ISIN: TW0007891004
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
24.05 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BoYen Therapeutics, Inc.
BoYen Therapeutics, Inc., through its own proprietary prodrug technology platform, engages in drug research and discovery. The company’s products include BY-101, used for treating acute myeloid leukemia (AML), and BY-102 and BY-103, for the treatment of multiple sclerosis and acute hematologic malignancies. The company was founded in 2010 and is headquartered in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6919
|
$5.46B
37K%
172.76B TWD
|
-
|
|
TWSE: 6949
|
$1.61B
11K%
50.93B TWD
|
-
|
|
TPEX: 6696
|
$1.08B
7K%
34.04B TWD
|
-
|
|
TWSE: 7827
|
$726.25M
5K%
22.97B TWD
|
-
|
|
|
TPEX: 7827
|
$600.25M
4K%
18.98B TWD
|
-
|
|
TPEX: 06891
|
$571.26M
4K%
18.06B TWD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
1M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
1M%
|
19.0
|
|
EBR: ARGX
|
$47.43B
319K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.23B
297K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.27B
284K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$41.88B
282K%
33.71B CHF
|
37.2
|
chevron_leftBack